S&P 500 slips on report Fed’s Waller leading race to replace Powell; tech shines
Rhonda Farnum, SVP, COMM & MEDICAL AFFAIRS at Theravance Biopharma, Inc. (NASDAQ:TBPH), sold 10,000 shares of company stock on July 14, 2025, according to a recent SEC Filing. The sales, executed in three separate transactions, fetched a total of $113,869.
The shares were sold at weighted average prices ranging from $11.3855 to $11.3927. Specifically, Farnum sold 682 shares at $11.3927, 5318 shares at $11.3855, and 4000 shares at $11.3879
The filing indicates that the sales were executed under a pre-arranged 10b5-1 trading plan adopted on March 14, 2024. InvestingPro subscribers can access 8 additional key insights about TBPH, including its unique market behavior with a beta of -0.02, indicating movement contrary to broader market trends.
In other recent news, Theravance Biopharma announced its first-quarter 2025 earnings, reporting a revenue of $15.4 million, which slightly exceeded analyst forecasts of $15.14 million. However, the company missed earnings per share (EPS) expectations, posting -$0.27 compared to the anticipated -$0.22. Additionally, Theravance Biopharma’s YUPELRI received approval from China’s National Medical (TASE:BLWV) Products Administration, marking a significant milestone for the company. This approval triggers a $7.5 million payment to Theravance, expected in the third quarter of 2025, and positions the company to earn up to $37.5 million in additional sales-based milestones in China.
In another development, Theravance Biopharma settled a patent litigation with Eugia Pharma, allowing Eugia to manufacture and market a generic version of YUPELRI in the U.S. starting April 2039. Meanwhile, BTIG maintained its Buy rating on Theravance Biopharma, raising the price target to $25 following the China approval of YUPELRI. The company also reported a strong cash position with $131 million and no debt, bolstered by a $225 million payment from the sale of TRELEGY royalties to GSK. Theravance Biopharma remains eligible for up to $150 million in potential milestones related to TRELEGY sales.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.